Andy Osborne is a research scientist at the University of Cambridge specialising in gene therapies to delay retinal ganglion cell loss and promote repair of the visual system. He obtained a degree in Biological Sciences and a PhD in Pharmacy from the University of East Anglia specialising in models of human retinal degeneration. Andy joined Professor Keith Martin at the John van Geest Brain Repair Centre in 2013 to investigate the mechanisms behind mesenchymal stem cells protection in the eye. He became principal researcher for the Cambridge gene therapy spin-out, Quethera, in 2015 and continues preclinical evaluation of novel constructs in collaboration with Astellas.